MindImmune Therapeutics Secures $10.2M Series A Extension, Total Funding Reaches $30M

Why It Matters

The infusion of $30 million positions MindImmune to advance its pipeline in a high‑growth, unmet‑need area of neurodegeneration, while attracting strategic investors like Pfizer signals industry confidence and could pave the way for future partnerships or acquisitions.

Deal Summary

Cambridge‑based MindImmune Therapeutics announced the close of a $10.2 million Series A extension, bringing its total Series A capital to $30 million. The round was led by Dolby Family Ventures with participation from Pfizer Ventures, Gates Frontier, Slater Technology Fund, RightHill Ventures and others.